Background: Valvular heart disease (VHD) is a known cardiac manifestation of systematic lupus erythematosus (SLE). This systematic review aims to pool data from studies to estimate the frequency of valvular lesions in SLE patients. It also aims to demonstrate the association between VHD in SLE and antiphospholipid antibodies positivity. Methods:We included 27 studies after identifying relevant abstracts from PubMed, Scopus, and Google Scholar from the time of inception of database to 2019. Inclusion criteria consisted of English-language casecontrol and cohort studies. Three reviewers independently performed study selection, data extraction, and quality assessment using the Newcastle-Ottawa Scale for assessing risk for bias.Results: For VHD in SLE patients, the most commonly involved valve was the mitral valve, with 19.7% lesions being mitral regurgitation. In terms of morphological lesions, valve thickening (11.06%) and vegetations (11.76%) were among the most prevalent. Other commonly encountered lesions were mitral valve prolapse and tricuspid regurgitation in 9.25% and 10.86% of patients, respectively. A meta-analysis of 21 studies with 2163 SLE patients, of which 23.3% had valvular lesions, showed a significant association of anticardiolipin antibodies positivity with VHD (relative risk, 1.55; confidence interval, 1.10-2.18).Conclusions: Systemic lupus erythematosus is associated with VHD, and it should be considered a clinical manifestation of SLE in the absence of other valvular pathologies. There is a clear association between VHD in SLE and immunoglobulin G anticardiolipin antibodies positivity. This association suggests that this subgroup of SLE patients might benefit from a screening echocardiogram.
Background Cardiac arrest carries high mortality and morbidity burden. Different studies showed conflicting data regarding outcomes of targeted temperature management (TTM) for cardiac arrest. The purpose of this meta-analysis is to systematically determine the effect of TTM on all-cause mortality and neurological outcomes after cardiac arrest. Methods We conducted a systematic search for randomized controlled trials in Pubmed, Cochrane & ScienceDirect. Primary outcomes were neurological outcome and all-cause mortality. Results Nine randomized controlled trials utilizing data for in-hospital and out-of-hospital cardiac arrest were selected for meta-analysis. Total number of patients included was 1592. Mortality was lower in targeted temperature management group (OR 0.637, 95% CI 0.436–0.93, p-value 0.019, I 2 = 44.78%, n = 1592). Therapeutic hypothermia group also demonstrated reduction in poor neurological outcomes (OR 0.582, 95% CI 0.363–931, p-value 0.024, I 2 = 56.79%, n = 1567). Subgroup analysis was conducted, after excluding in-hospital cardiac arrest patients, and demonstrated reduction in poor neurological outcome (OR 0.562, 95% CI 0.331–0.955, p-value 0.033, I 2 = 61.78%, n = 1480) and mortality in out-of-hospital cardiac arrest patients (OR 0.674, 95% CI 0.454–999, p-value 0.049, I 2 = 43.8%, n = 1505). Conclusion Targeted temperature management after cardiac arrest may be associated with improvement in all-cause mortality and reduction in poor neurological outcome.
Background: Upregulation of Programmed Death-Ligand 1 (PD-L1) in tumor cells results in the deactivation of cytotoxic T cells in the tumor microenvironment and development of tolerance to the malignant cells. We aimed to investigate the role of PD-L1 expression in early stage breast cancer and its correlation with tumor characteristics as well as assess the relationship between PD-L1 membrane protein and gene expression. Methods: For this single center, retrospective study, women (age >18 years) with early stage breast cancer diagnosed between January 2005 and December 2005 were enrolled. Key inclusion criteria for enrollment were pathologic diagnosis of DCIS or invasive ductal/lobular carcinoma, stage 0-2, with local resection done in 2005. Patients had to have adequate formalin-fixed paraffin-embedded tumor specimens for PD-L1 testing. We hypothesized that higher levels of PD-L1 expression correlates with more aggressive disease and worse prognosis. We used histopathological analysis, medical chart review, and PD-L1 expression via immunohistochemistry (IHC) and reverse transcription polymerase chain reaction (RT-PCR) for data analysis. Chi Square and one way ANOVA analyses were used to compare clinical and pathological characteristics of patients with high and low PD-L1 expression. Results In 2005, 368 women were diagnosed with breast cancer at Providence-Providence Park Hospital of which 31 pathological specimens were obtained for exploratory analysis. PD-L1 protein expression was determined to be positive if more than 1% of the tumor cells showed partial or complete membrane staining for PD-L1 by IHC. All patients with DCIS (n=7) were negative for PDL-1 expression although 3 showed gene expression by PCR. After excluding the DCIS specimens, 17% (4/24) of early stage breast cancer was found to express PD-L1 protein. Seven of 24 specimens (excluding DCIS) were positive for PD-L1 RNA by RT-PCR. There was no relationship between PD-L1 protein and mRNA expression (p=0.552). 75% of the PD-L1 positive specimens by IHC were also ER positive although this was not statistically significant (p=0.312). There was a trend toward larger tumors for those expressing PD-L1 on the cell surface (mean size of 2.7 cm vs 1.7 cm, p= 0.07). All the PD-L1 positive specimens had increased lymphocyte infiltration, although no statistical significance was observed. At 10 years from initial diagnosis, all-cause mortality rate was 29% (7/24). The rate of death in PD-L1 positive patients was 2/4 (50%) compared to 5/20 (25%) in PD-L1 negative group. Conclusion: Expression of PD-L1 in early stage breast cancer could be an important indicator for more aggressive disease and supports investigating checkpoint inhibitors in this population. Further investigation is needed to determine its applicability in clinical decisions and effects on treatment. Citation Format: Hadeel Assad, Juan Cattoni, Subramanyeswara Arekapudi, Nancy Jackson, Hugo Macchi Cattoni, Sherri Motahari, Hema Govil, Anibal Drelichman. Correlation between PD-L1 expression and tumor clinicopathologic characteristics in early stage breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5006. doi:10.1158/1538-7445.AM2017-5006
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.